
|Articles|September 16, 2008
- July15 2003
- Volume 10
- Issue 13
FUND SUPERMARKETS
Author(s)Michael Sheehan
Advertisement
One-stop shopping for mutualfunds through a fund supermarketlike Fidelity Fund Network (800-343-3548) can be convenient andmay even save you money. You maybe able to buy into an institutionalversion of your favorite fund andenjoy a lower expense ratio, andminimum investments may be lower.Buying funds that aren't on the fundsupermarket's list can be expensive,though, and the list of nonparticipatingfunds is likely to get longer. Fundsupermarkets are upping the ante byraising the fees they charge funds tobe listed, which may lead somefunds to drop out.
Articles in this issue
about 18 years ago
Less Time, More Workabout 18 years ago
One Hand Giving, Another Taking?about 18 years ago
RIP-Steven C. Campabout 18 years ago
Pay Yourself Firstabout 18 years ago
ADDING TO THE MIXabout 18 years ago
SPAMMER SLAMMEDabout 18 years ago
AUDITING THE WEALTHYabout 18 years ago
UNDER THE IRS GUNabout 18 years ago
MEDICARE RUNAROUNDabout 18 years ago
REFINANCING & TAXESAdvertisement
Related to this article

Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.

This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.

Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.

George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.

Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.

Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.

SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5

